Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?
9/11 15:35
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are locked in an intensifying conflict for control over the markets for weight loss and type 2 diabetes treatments. Novo Nordisk's diabetes therapy Ozempic is the leader of the pack at the moment, generating upwards of $3 billion...